Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Operating Expenses (2016 - 2025)

Rein Therapeutics filings provide 10 years of Operating Expenses readings, the most recent being $32.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 23.69% year-over-year to $32.7 million, compared with a TTM value of $50.6 million through Dec 2025, down 22.24%, and an annual FY2025 reading of $50.6 million, down 22.24% over the prior year.
  • Operating Expenses hit $32.7 million in Q4 2025 for Rein Therapeutics, up from $5.5 million in the prior quarter.
  • The five-year high for Operating Expenses was $42.8 million in Q4 2024, with the low at $2.0 million in Q3 2023.
  • Median Operating Expenses over the past 5 years was $6.8 million (2021), compared with a mean of $9.3 million.
  • The sharpest move saw Operating Expenses tumbled 75.23% in 2023, then skyrocketed 487.06% in 2024.
  • Year by year, Operating Expenses stood at $6.8 million in 2021, then plummeted by 31.0% to $4.7 million in 2022, then surged by 55.01% to $7.3 million in 2023, then soared by 487.06% to $42.8 million in 2024, then dropped by 23.69% to $32.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $32.7 million, $5.5 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.